Recent events
Recent events tied to this brand in public sources.
Back to profile33 entries · Page 2 of 2
2020
Dr. Reddy’s partners with Fujifilm and GRA on Avigan
Dr. Reddy’s Laboratories announced a tripartite agreement with Fujifilm Corporation and Global Response Aid to develop, manufacture and sell Avigan tablets in specified markets, subject to applicable approvals.
2020
Dr. Reddy’s completes acquisition of selected Wockhardt business divisions
Dr. Reddy’s Laboratories completed its acquisition of selected divisions of Wockhardt’s branded generics business in India and several other territories. The transferred business included 62 brands, related sales and marketing teams, and a manufacturing plant.
2020
Midatech Pharma and Dr. Reddy’s enter research collaboration
Midatech Pharma announced that it had entered into a research collaboration with Dr. Reddy’s, applying Midatech's drug-delivery technologies to existing medicines.
2020
Dr. Reddy’s recalls Esomeprazole Magnesium capsules
Dr. Reddy’s is voluntarily recalling 1,752 bottles of generic Esomeprazole Magnesium delayed-release capsules in the US after the USFDA identified discoloration and brown pellets in the product. The report says it is a Class III recall.
2020
FDA approves Dr. Reddy’s Elyxyb application
Dr. Reddy’s Laboratories said the US Food and Drug Administration approved its new drug application for Elyxyb, a celecoxib oral solution indicated for acute migraine treatment in adults.
2020
Dr Reddy's launches Invista in India
Dr Reddy's Laboratories said it launched Invista, a generic blood cancer drug, in India. Invista is a formulation of Dasatinib and is available in 50, 70 and 100 mg tablets.
2020
Dr. Reddy's launched generic pyrimethamine tablets
Dr. Reddy's Laboratories announced the launch of Pyrimethamine Tablets USP, 25 mg, a therapeutic equivalent of Daraprim tablets; the company said it was the only FDA-approved AB-rated generic version.
2020
Dr Reddy's launches generic Vimovo tablets in the US
Dr Reddy's Laboratories said it launched the first generic version of Vimovo tablets in the US market. The product is naproxen and esomeprazole magnesium delayed-release tablets, approved by the US FDA.
2019
Dr. Reddy’s announces launch of Deferasirox Tablets for Oral Suspension
Dr. Reddy’s Laboratories announced the launch of Deferasirox Tablets for Oral Suspension, a therapeutically equivalent generic version of Exjade approved by the USFDA. The tablets are available in 125 mg, 250 mg, and 500 mg strengths.
2019
Dr Reddy’s launches doxercalciferol injection in the US
Dr Reddy’s Laboratories launched doxercalciferol injection in the US market as a therapeutic generic equivalent of Hectorol injection approved by the USFDA.
2019
Dr. Reddy's launches Celevida nutrition drink in India
Dr. Reddy's Laboratories launched Celevida, a diabetes nutrition drink, as its entry into India's domestic nutrition segment.
2019
Court denies Dr. Reddy’s summary judgment motion in VIMOVO patent litigation
The United States District Court for the District of New Jersey denied a motion for summary judgment filed by Dr. Reddy’s Laboratories in Nuvo-related litigation over two VIMOVO patents, so the patent infringement litigation would continue. Nuvo said it believed the patents were valid and enforceable; the court decision reported here concerned the motion, not a final determination of infringement.
2019
Dr. Reddy's recalls ranitidine lots in the US
Dr. Reddy's initiated a voluntary recall of several lots of its ranitidine products in the US after confirmed contamination with NDMA above levels established by the FDA. The recall began on October 1.